A new large phase three trial found that one such drug, daraxonrasib, roughly doubled survival compared to standard chemotherapy

Yes, from 7 months to 14. This detail which the article omits and assumes the reader will not notice or factcheck. This is a recuring these of "works in progress" articles of making sweeping claims or omitting details.